|
1
|
Savoia F, Medri M, Passardi A, Melandri D, Stanganelli I. Gemcitabine, a rare cause of chemotherapy-related reticulate hyperpigmentation. Dermatol Reports 2024; 16:9872. [PMID: 39583048 PMCID: PMC11582954 DOI: 10.4081/dr.2024.9872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Accepted: 11/12/2023] [Indexed: 11/26/2024] Open
Abstract
Reticulate pigmentary disorders can be classified into inherited or acquired and cutaneous drug- induced reticulate hyperpigmentation belongs to this last group. The list of the drugs involved is constantly increasing and chemotherapy agents are frequently implicated. We report a new case of chemotherapy-related reticulate hyperpigmentation to gemcitabine, even though a previous chemotherapy with nanoparticle, albumin-bound (Nab®) paclitaxel and gemcitabine may have promoted the onset of the disease. Reassurance of the patients is important in these cases, in order to continue the chemotherapy, and gradual fading of the hyperpigmentation is usually observed, as in our case.
Collapse
Affiliation(s)
- Francesco Savoia
- Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC)
| | - Matelda Medri
- Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC)
| | - Alessandro Passardi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC)
| | - Davide Melandri
- Dermatology Unit, Bufalini Hospital, Cesena (FC)
- Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna
| | - Ignazio Stanganelli
- Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC)
- Department of Clinical and Experimental Medicine, Parma, Italy
| |
Collapse
|
|
2
|
Kumar S, Bhattacharjee R, Kambhampati SBN, Narang T, Kanwar AJ, Vinay K. Chemotherapy-induced reticulate pigmentation in three Indian patients including a case in the pediatric age group. Indian J Dermatol Venereol Leprol 2021; 87:386-388. [PMID: 33943060 DOI: 10.25259/ijdvl_216_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2020] [Accepted: 11/01/2020] [Indexed: 11/04/2022]
Affiliation(s)
- Sheetanshu Kumar
- Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Rajsmita Bhattacharjee
- Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | | | - Tarun Narang
- Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | | | - Keshavamurthy Vinay
- Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| |
Collapse
|
|
3
|
Sanke S, Mendiratta V, Jassi R, Yadav J, Chander R. Rituximab induced reticulate pigmentation over face in pemphigus vulgaris. Dermatol Ther 2020; 33:e13752. [PMID: 32519811 DOI: 10.1111/dth.13752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 05/04/2020] [Accepted: 05/24/2020] [Indexed: 11/26/2022]
Affiliation(s)
- Sarita Sanke
- Department of Dermatology and STD, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India
| | - Vibhu Mendiratta
- Department of Dermatology and STD, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India
| | - Rubina Jassi
- Department of Dermatology and STD, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India
| | - Jyoti Yadav
- Department of Dermatology and STD, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India
| | - Ram Chander
- Department of Dermatology and STD, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India
| |
Collapse
|
|
4
|
Cohen PR. Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation. World J Clin Cases 2016; 4:390-400. [PMID: 28035312 PMCID: PMC5156876 DOI: 10.12998/wjcc.v4.i12.390] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2016] [Revised: 09/19/2016] [Accepted: 10/24/2016] [Indexed: 02/05/2023] Open
Abstract
Drug-induced reticulate hyperpigmentation is uncommon. Including the patient described in this report, chemotherapy-associated reticulate hyperpigmentation has only been described in ten individuals. This paper describes the features of a woman with recurrent and metastatic breast cancer who developed paclitaxel-induced reticulate hyperpigmentation and reviews the characteristics of other oncology patients who developed reticulate hyperpigmentation from their antineoplastic treatment. A 55-year-old Taiwanese woman who developed reticulate hyperpigmentation on her abdomen, back and extremities after receiving her initial treatment for metastatic breast cancer with paclitaxel is described. The hyperpigmentation became darker with each subsequent administration of paclitaxel. The drug was discontinued after five courses and the pigment faded within two months. PubMed was searched with the key words: Breast, cancer, chemotherapy, hyperpigmentation, neoplasm, reticulate, tumor, paclitaxel, taxol. The papers generated by the search, and their references, were reviewed. Chemotherapy-induced reticulate hyperpigmentation has been described in four men and six women. Bleomycin, cytoxan, 5-fluorouracil, idarubacin, and paclitaxel caused the hyperpigmentation. The hyperpigmentation faded in 83% of the patients between two to six months after the associated antineoplastic agent was discontinued. In conclusion, chemotherapy-induced reticulate hyperpigmentation is a rare reaction that may occur during treatment with various antineoplastic agents. The hyperpigmentation fades in most individuals once the treatment is discontinued. Therefore, cancer treatment with the associated drug can be continued in patients who experience this cutaneous adverse event.
Collapse
|
|
5
|
Masson Regnault M, Gadaud N, Boulinguez S, Tournier E, Lamant L, Gladieff L, Roche H, Guenounou S, Recher C, Sibaud V. Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature. Dermatology 2015; 231:312-8. [PMID: 26422424 DOI: 10.1159/000439047] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 07/27/2015] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Inherited or acquired reticulate hyperpigmentation represents a heterogeneous group of infrequent dermatological conditions. The development of reticulate hyperpigmentation has so far been rarely reported to be associated with chemotherapeutic agents, including fluorouracil, bleomycin or a combination of cytarabine and idarubicin. CASE REPORTS We describe 5 cases of chemotherapy-related reticulate hyperpigmentation in patients treated with different chemotherapeutic regimens, in particular paclitaxel or cytarabine. The lesions were similar in all cases, with reticulate and/or linear hyperpigmented streaks, which were mainly located to the back and buttocks. Histology showed increased melanogenesis, which suggests a direct toxic effect of chemotherapy on melanocytes. Reflectance confocal microscopy was performed in 2 patients showing a similar pattern, with an increased amount of melanin in basal keratinocytes. These features have been compared with the available data through a literature review. CONCLUSION Reticulate hyperpigmentation is an underestimated but characteristic complication of chemotherapy. Neither specific management nor discontinuation of the chemotherapeutic regimen is required.
Collapse
Affiliation(s)
- Marie Masson Regnault
- Department of Dermatology, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
|
6
|
Grynszpan R, Niemeyer-Corbellini JP, Lopes MSS, Ramos-e-Silva M. Bleomycin-induced flagellate dermatitis. BMJ Case Rep 2013; 2013:bcr-2013-009764. [PMID: 23814202 DOI: 10.1136/bcr-2013-009764] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Flagellate dermatitis shows very characteristic lesions: linear erythema or hyperpigmentation in various areas of the skin. It is a side effect of bleomycin, an immunosupressive drug used for several types of cancers. All physicians must be aware of this disease so they can make a rapid diagnosis and interrupt the causative agent. Our patient presented during chemotherapy for a Hodgkin's lymphoma pruritic, erythematous lesions on the lower limbs and the back diagnosed as flagellate dermatitis due to bleomycin.
Collapse
Affiliation(s)
- Rachel Grynszpan
- Sector of Dermatology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | | | | | | |
Collapse
|
|
7
|
Sibaud V, Fricain JC, Baran R, Robert C. Anomalies pigmentaires induites par les traitements anticancéreux. Première partie : les chimiothérapies. Ann Dermatol Venereol 2013; 140:183-96. [DOI: 10.1016/j.annder.2012.12.012] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2012] [Revised: 10/31/2012] [Accepted: 12/05/2012] [Indexed: 02/06/2023]
|
|
8
|
Sanz-Sánchez T, Córdoba S, Jiménez-Ayala B, Borbujo J. Hiperpigmentación reticulada inducida por 5-fluorouracilo. ACTAS DERMO-SIFILIOGRAFICAS 2008. [DOI: 10.1016/s0001-7310(08)74748-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
|
9
|
Sanz-Sánchez T, Córdoba S, Jiménez-Ayal B, Borbujo J. 5-Fluorouracil-Induced Reticular Hyperpigmentation. ACTAS DERMO-SIFILIOGRAFICAS 2008. [DOI: 10.1016/s1578-2190(08)70319-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
|
10
|
|
|
11
|
Abstract
Bleomycin is frequently used as a chemotherapeutic agent to treat various kinds of malignancy. However, the cytotoxic effects of bleomycin cause a number of adverse responses, in particular in the lung and the skin. Bleomycin is used by dermatologists as a treatment for various skin cancers, recalcitrant warts, keloid and hypertrophic scars. This article discusses the use of bleomycin for various skin disorders, as well as the risk factors and cutaneous side-effects resulting from its use.
Collapse
Affiliation(s)
- T Yamamoto
- Department of Dermatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Tokyo 160-0023, Japan.
| |
Collapse
|
|
12
|
Zengin G, Artüz F, Lenk N, Allí N. Raynaud's phenomenon following intralesional bleomycin injection. J Eur Acad Dermatol Venereol 2006. [DOI: 10.1111/j.1468-3083.1997.tb00470.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
|
13
|
Affiliation(s)
- N Nayak
- Department of Dermatology, Southampton University Hospitals Trust, UK
| | | | | |
Collapse
|
|
14
|
Affiliation(s)
- N G Rubeiz
- Department of Dermatology, American University of Beirut Medical Center, Lebanon
| | | | | | | |
Collapse
|
|
15
|
Discussion of questions 20–29. J Am Acad Dermatol 1995. [DOI: 10.1016/0190-9622(95)91856-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
|
16
|
|
|
17
|
Abstract
The progression of vitiligo and postinflammatory hyperpigmentation simultaneously in a patient with AIDS led to the appearance of a blue color on much of the patient's skin. The blue coloration subsequently resolved with follicular repigmentation typical of resolving vitiligo. We believe this is the first reported case of "blue vitiligo."
Collapse
Affiliation(s)
- R Ivker
- Dermatology Service, Department of Veterans Affairs Medical Center, New York, NY 10010
| | | | | |
Collapse
|
|
18
|
Affiliation(s)
- A J McDonagh
- Department of Dermatology, Royal Hallamshire Hospital, Sheffield, United Kingdom
| | | | | | | |
Collapse
|